EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

PD1-Targeted Transgene Delivery to Treg Cells

Vladislav A Zhuchkov iD, Yulia E Kravchenko, Elena I Frolova, Stepan P Chumakov iD

Viruses · 2024

DOI: 10.3390/v16121940 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Viruses, 2024. Verfasst von Vladislav A Zhuchkov und 3 weiteren Autor:innen. Beteiligte Einrichtung: Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117997 Moscow, Russia. Hauptthemen laut MEDLINE: T-Lymphocytes, Regulatory, Programmed Cell Death 1 Receptor, Genetic Vectors, Transgenes. Die Arbeit nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Russian Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Achieving the precise targeting of lentiviral vectors (LVs) to specific cell populations is crucial for effective gene therapy, particularly in cancer treatment where the modulation of the tumor microenvironment can enhance anti-tumor immunity. Programmed cell death protein 1 (PD-1) is overexpressed on activated tumor-infiltrating T lymphocytes, including regulatory T cells that suppress immune responses via FOXP3 expression. We developed PD1-targeted LVs by incorporating the anti-PD1 nanobody nb102c3 into receptor-blinded measles virus H and VSV-Gmut glycoproteins. We assessed the retargeting potential of nb102c3 and evaluated transduction efficiency in activated T lymphocytes. FOXP3 expression was suppressed using shRNA delivered by these LVs. Our results demonstrate that PD1-targeted LVs exerted pronounced tropism towards PD1+ cells, enabling the selective transduction of activated T lymphocytes while sparing naive T cells. The suppression of FOXP3 in Tregs reduced their suppressive activity. PD1-targeted glycoprotein H provided greater specificity, whereas the VSV-Gmut, together with the anti-PD1 pseudoreceptor, achieved higher viral titers but was less selective. Our study demonstrates that PD1-targeted LVs may offer a novel strategy to modulate immune responses within the tumor microenvironment with the potential for developing new therapeutic strategies aimed at enhancing anti-tumor immunity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

T-Lymphocytes, RegulatoryProgrammed Cell Death 1 ReceptorGenetic VectorsTransgenesHumansLentivirusForkhead Transcription FactorsTransduction, GeneticAnimalsGenetic TherapyMiceTumor MicroenvironmentGene Transfer TechniquesSingle-Domain Antibodies

Stichwörter der Autor:innen

FOXP3PD1Treglentivectornanobodyretargeting

Substanzen

Programmed Cell Death 1 ReceptorForkhead Transcription FactorsPDCD1 protein, humanSingle-Domain Antibodies

Autor:innen und Institutionen

  • Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117997 Moscow, Russia.
  • Biomarker Research Laboratory, Institute of Fundamental Medicine and Biology, Kazan Federal University, 420008 Kazan, Russia.

ORCID-Profile: Vladislav A Zhuchkov, Stepan P Chumakov

Förderung

  • Russian Science Foundation

Zitieren

APA

Zhuchkov, V. A., Kravchenko, Y. E., Frolova, E. I., & Chumakov, S. P. (2024). PD1-Targeted Transgene Delivery to Treg Cells. Viruses. https://doi.org/10.3390/v16121940

Vancouver

Zhuchkov VA, Kravchenko YE, Frolova EI, Chumakov SP. PD1-Targeted Transgene Delivery to Treg Cells. Viruses. 2024. doi:10.3390/v16121940

BibTeX
@article{Zhuchkov2024,
  author = {Zhuchkov, Vladislav A and Kravchenko, Yulia E and Frolova, Elena I and Chumakov, Stepan P},
  title = {PD1-Targeted Transgene Delivery to Treg Cells},
  journal = {Viruses},
  year = {2024},
  doi = {10.3390/v16121940}
}
Kostenlos starten →